secwatch.observer — SEC 8-K summary
======================================

Issuer:     NANOVIRICIDES, INC. (NNVC)
CIK:        0001379006
Form:       8-K
Filed at:   2025-10-01T23:59:59+00:00
Accession:  0001104659-25-095676
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

NanoViricides extends CEO/CFO contracts; raises CEO line of credit to $3M through 2027
--------------------------------------------------------------------------------

- President/CEO Diwan term extended to June 30, 2026; base salary $400,000/yr; granted 10,204 Series A preferred shares vesting quarterly.
- CFO Vyas term extended to June 30, 2026; compensation $10,800/month; health insurance reimbursement up to $2,500/month.
- CEO Diwan's line of credit increased from $2M to $3M; maturity extended to March 31, 2027; 12% interest; secured by company property.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1379006/000110465925095676/0001104659-25-095676-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1379006/000110465925095676/tm2527703d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-095676

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer